IRCT20090117001556N128
Recruiting
Phase 2
Sulforaphane as a treatment for mild to moderate depression in post percutaneous coronary intervention patients: A randomized double blind and placebo controlled clinical trial
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Depression.
- Sponsor
- Tehran University of Medical Sciences
- Enrollment
- 50
- Status
- Recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Based on DSM\-5 diagnostic criteria, have minor depression disorder
- •Based on Hamilton depression scale, get the score of 14 to 17
- •Age between 40 to 65 years
- •History of percutaneous coronary intervention
Exclusion Criteria
- •Pregnant or lactating women
- •Presence of other psychiatric disorders
- •Be psychotic
- •History of Electroconvulsive therapy, two months prior to the trial
- •Using psychotropic drug
- •Drug addiction
- •Presence of Thyroid disease
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Saffron and AlzheimerIRCT138711051556N1Tehran University of Medical Sciences50
Recruiting
Phase 2
Sulforaphane for the treatment of ADHDIRCT20090117001556N146Tehran University of Medical Sciences50
Completed
Phase 3
Saffron in the treatment of OCDL a randomisedObsessive- Cumpulsive Disorder.Obsessive-compulsive disorderIRCT201407151556N62Tehran University of Medical Sciences50
Withdrawn
Phase 2
Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer ChemopreventionBladder CancerBladder TumorUrothelial CarcinomaNCT03517995H. Lee Moffitt Cancer Center and Research Institute
Recruiting
Phase 2
The effect of sulforaphane on depression in women with PCOSSeverity of depression.Polycystic ovarian syndromeE28.2IRCT20090117001556N144Tehran University of Medical Sciences50